Needham Keeps Buy Rating on Revolution Medicines (RVMD) Despite Wider Loss
Quick Take
Needham maintains a Buy rating on Revolution Medicines despite a reported wider loss.
Key Points
- Revolution Medicines reported a wider financial loss.
- Needham analysts remain optimistic about the company's future.
- Stock rating remains unchanged at Buy.
Reader Mode unavailable (could not extract clean content).
Want this in your inbox every morning?
Daily brief at your local 8am — bilingual EN/中文, free.
More from Yahoo Finance
See more →
1d ago
FeaturedOriginal
These Super Stocks Could Be the Biggest Winners in the AI Inference and Agentic AI Economy
AI Summary
The article highlights top stocks poised for growth in the AI inference and agentic AI sectors.
